PDS Biotechnology Corporation

139 articles with PDS Biotechnology Corporation

• PDS Biotech Receives $4.5M After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program

  5/17/2021

  PDS Biotechnology Corporation announced the receipt of $4.5 million from the net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant to the Company’s participation in the New Jersey Technology Business Tax Certificate Transfer Net Operating Loss program for State Fiscal Year 2020.

• PDS Biotech Provides Business Update and Reports First Quarter 2021 Financial Results

  5/13/2021

  PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, will discuss its financial results for the quarter ended March 31, 2021 and provide a business update on its conference call.

• PDS Biotechnology Announces Participation in Noble Capital Markets C-Suite Interview Series - May 12, 2021

  5/12/2021

  PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, announced their participation in Noble Capital Markets’ C-Suite Interview Series, presented by Channelchek.

• PDS Biotech Announces Oral Presentation of PDS0101 Data by the National Cancer Institute at 2021 American Society of Clinical Oncology Annual Meeting

  4/29/2021

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that initial efficacy and safety data from the National Cancer Institute’s (NCI) Phase 2 clinical study of PDS0101

• PDS Biotechnology Announces Conference Call and Webcast for First Quarter Financial Results

  4/26/2021

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating technology, today announced that the Company will release financial results for the first quarter of 2021 on Thursday, May 13, 2021, before the market opens.

• PDS Biotech Announces Participation in Noble Capital Markets Virtual Road Show Series

  4/19/2021

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced their participation in Noble Capital Markets’ Virtual Road Show Series, presented by Channelchek, scheduled for April 21, 2021.

• PDS Biotech Reports Financial Results for the Year Ended December 31, 2020 and Provides Business Update

  3/18/2021

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating technology, today announced its financial results for the year ended December 31, 2020 and provided a business update.

• PDS Biotech Announces that its COVID-19 Vaccine Consortium Received a Commitment from MCTI to fund Clinical Development and Commercialization of a Versamune®-Based COVID-19 Vaccine with an Award of up to Approximately US$60 million

  3/11/2021

  Development and commercialization of novel T-cell activating vaccine to be performed in Brazil by consortium of PDS Biotech, Farmacore Biotechnology and Blanver Farmoquímica

• PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter and Full Year 2020 Financial Results

  3/8/2021

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that the Company will release financial results for the three- and twelve-month periods ended December 31, 2020 on Thursday, March 18,

• PDS Biotech Announces Presentations in Upcoming Healthcare Investor Conferences

  3/3/2021

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that Frank Bedu-Addo, CEO of PDS Biotech, will present at the H.C. Wainwright Global Life Sciences Conference

• PDS Biotech and Farmacore Announce Blanver to Join Consortium to Commercialize Novel Versamune®-Based T-Cell Inducing COVID-19 Vaccine

  2/22/2021

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, and Farmacore Biotechnology today announced that Blanver Farmoquímica e Farmacêutica S.A. has joined their consortium to develop and commercialize a novel COVID-19 vaccine in Latin America.

• PDS Biotech Announces Preliminary Efficacy Achievement in Phase 2 Combination Trial of PDS0101 Led by the National Cancer Institute

  2/3/2021

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that the National Cancer Institute’s (NCI) Phase 2 clinical study of PDS0101 for the treatment of advanced human papillomavirus (HPV)-associated cancers that have progressed or returned after treatment

• PDS Biotech Releases White Paper Detailing the Potential of the Versamune® Platform in Overcoming a Major Limitation of Immuno-OncologyPromotes in-vivo tumor-attacking killer T-cells to facilitate cancer treatment

  1/14/2021

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today released a white paper detailing how the Versamune® platform works to treat cancer, and the potential of Versamune® in the treatment of a broad range of cancers.

• PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  1/6/2021

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that the Compensation Committee of the PDS Board of Directors approved the grant of inducement stock options covering an aggregate of 202,800 shares of PDS Biotech’s common stock

• PDS Biotech Announces Participation in H.C. Wainwright BioConnect 2021 Virtual Conference

  1/5/2021

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that Chief Executive Officer Dr. Frank Bedu-Addo will be presenting at H.C. Wainwright’s BioConnect virtual conference. PDS Biotech’s presentation will be available on-demand beginning January 11, 2021

• PDS Biotech Announces Mount Sinai Publication of Studies Showing Superior Induction of Antibodies by Versamune®-based COVID-19 Vaccine Versamune®

  12/21/2020

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced the publication of data generated by a leading vaccine research team at the Icahn School of Medicine at Mount Sinai. The research demonstrated powerful antibody induction by Versamune® against SARS-CoV

• PDS Biotechnology Appoints Seth Van Voorhees as Chief Financial Officer

  12/9/2020

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced the appointment of Seth Van Voorhees, Ph.D. as its new Chief Financial Officer effective January 1, 2021.

• PDS Biotech Announces New and Broad Versamune® Platform Patent ClaimsGranted methods patent for Versamune® platform by the United States Patent and Trademark Office

  11/16/2020

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that it has been granted U.S. Patent No. 10,828,364 titled “Method for Reducing a Myeloid Derived Suppressor Cell Population With Cationic Lipid Vaccine Compositions” by the United States Patent and Tr

• PDS Biotech to Present at the Virtual Fall Investor Summit on November 16th-18th

  11/13/2020

  PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, announced that Dr. Frank Bedu-Addo, Chief Executive Officer, will be presenting at this year's virtual Fall Investor Summit taking place November 16th-18th, 2020.

• PDS Biotechnology Reports Financial Results for the Third Quarter 2020 and Provides Business Update

  11/11/2020

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced its financial results for the third quarter ended September 30, 2020 and provided a business update.